Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD20 CAR T cells C-CAR066

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20), with potential immunostimulating and antineoplastic activities. Upon administration, C-CAR066 specifically recognize and kill CD20-expressing tumor cells. The CD20 antigen, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies and certain melanoma cell subpopulations.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous anti-CD20 CAR T cells C-CAR066 CBM.CD20 CAR T C-CAR066
Code name:	C CAR066 C-CAR066 CCAR066

anti-CD20 CAR T cells C-CAR066

Search NCI's Drug Dictionary